Drug Discovery
Eli Lilly signs a potential $2.75B AI-driven drug discovery pact with Insilico
Lilly is doubling down on the "AI platform" bet — but with milestone economics that keep downside limited. The company signed a multi-program collaboration with Insilico Medicine worth up to $2.75 billion across milestones and option payments, aiming to push multiple AI-designed candidates from target selection into clinical development. Insilico’s pitch is speed: compress the early discovery loop by combining generative chemistry with automated validation, then hand off to a pharma that can actually run trials at scale. The tell is the structure: big headline number, but value accrues only if programs clear real development gates.
Source: pharmaphorum.com